Please ensure Javascript is enabled for purposes of website accessibility
TUCC | The Urology Center of Colorado Logo

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study

TUCC physician, Lawrence Karsh, M.D., was a lead principal investigator in this Phase III clinical trial, published in The Lancet in February 2011.

Read Article

We’re here to help.

For appointments at any TUCC location, request an appointment online.